GO:0046068 cGMP metabolic process: Genes and Research

Cyclic GMP (cGMP) is a cyclic nucleotide second messenger that regulates diverse physiological processes, including smooth muscle relaxation, cardiac contractility, retinal phototransduction, and neuronal signaling. The Gene Ontology term GO:0046068, cGMP metabolic process, encompasses the chemical reactions and pathways involving cyclic GMP, guanosine 3',5'-phosphate. This term captures both the synthesis of cGMP from GTP by guanylyl cyclases and its breakdown by cyclic nucleotide phosphodiesterases, as well as transport mechanisms that control intracellular and extracellular cGMP levels. Understanding cGMP metabolism is fundamental because perturbations in this pathway underlie multiple human diseases, from cardiovascular disorders to neurodegeneration. Research into cGMP metabolic process has revealed that cGMP signals through effectors such as cGMP-dependent protein kinases (cGKI and cGKII), cyclic nucleotide-gated channels, and phosphodiesterases. In the vasculature, cGMP mediates nitric oxide-induced vasodilation, and its dysregulation contributes to hypertension and atherosclerosis. In the retina, excessive cGMP accumulation leads to metabolic stress and photoreceptor degeneration. Moreover, age-related changes in cGMP metabolism have been observed in human granulocytes, linking this pathway to oxidative stress and aging. Given its broad physiological impact, cGMP metabolic process is a major focus for pharmacological and genetic studies. Researchers employ knockout and knock-in models, phosphodiesterase inhibitors, and advanced omics technologies to dissect the pathway's components and their roles in health and disease. This article provides a comprehensive overview of the ontology, key genes, regulatory mechanisms, disease associations, and experimental strategies for studying cGMP metabolic process.

GO:0046068 (cGMP metabolic process) is defined as the chemical reactions and pathways involving cyclic GMP, guanosine 3',5'-phosphate. This biological process includes the biosynthesis of cGMP from GTP by guanylyl cyclases, the hydrolysis of cGMP to 5'-GMP by phosphodiesterases, and the transport of cGMP across cellular membranes. It also encompasses the downstream signaling events directly mediated by cGMP as a second messenger, such as activation of cGMP-dependent protein kinases and ion channels.

cGMP metabolic process is critically important because cGMP serves as a ubiquitous second messenger that translates nitric oxide and natriuretic peptide signals into cellular responses, including smooth muscle relaxation, cardiac remodeling, and neuronal plasticity. Disruptions in cGMP synthesis, degradation, or transport are linked to hypertension, heart failure, retinal degeneration, and neurodegenerative conditions such as Alzheimer's disease. Therefore, understanding the molecular players and regulatory mechanisms of cGMP metabolism is essential for developing targeted therapies and for interpreting genetic and pharmacological perturbations in disease models.

The following genes encode core components of the cGMP metabolic process, including synthesizing enzymes, degrading enzymes, transporters, and downstream effectors.

cGMP metabolic process is regulated at multiple levels. Synthesis by guanylyl cyclases is controlled by nitric oxide, natriuretic peptides, and calcium. Degradation by phosphodiesterases is regulated by allosteric cGMP binding, phosphorylation, and subcellular localization. Transporters such as ABCC4 and ABCC5 modulate intracellular cGMP levels. Downstream, cGMP-dependent protein kinases are regulated by cGMP binding, autophosphorylation, and interaction with anchoring proteins. Additionally, cross-talk with cAMP signaling and calcium pathways fine-tunes cGMP responses.

cGMP metabolic process is central to cardiovascular homeostasis. Nitric oxide-induced cGMP production in vascular smooth muscle causes relaxation and lowers blood pressure. In heart failure, impaired cGMP signaling contributes to pathological remodeling, and cGMP-dependent protein kinase I (PRKG1) activity is altered. Polymorphisms in NOS3 and GUCY1A1 are associated with hypertension and coronary artery disease. Therefore, targeting cGMP synthesis or degradation is a therapeutic strategy for cardiovascular disorders.

In the retina, cGMP is essential for phototransduction, but excessive cGMP is toxic. Mutations in PDE6A or PDE6B cause cGMP accumulation, leading to photoreceptor death and retinitis pigmentosa. Similarly, mutations in GUCY2D or CNGA1/CNGB1 disrupt cGMP metabolism and cause Leber congenital amaurosis or retinitis pigmentosa. Studies in animal models show that excessive cGMP impacts metabolic proteins at the onset of degeneration, suggesting metabolic stress as a key mechanism.

The interplay between cGMP and calcium signaling is implicated in Alzheimer's disease. Dysregulated cGMP levels can affect neuronal plasticity, synaptic function, and amyloid-beta toxicity. Modulating cGMP pathways, such as through phosphodiesterase inhibitors, is being explored as a therapeutic approach for cognitive decline.

Age-related changes in cGMP metabolism have been observed in human granulocytes, where an imbalance among cAMP, cGMP, and reactive oxygen intermediates contributes to functional decline. Additionally, cGMP signaling influences metabolic processes in various tissues, and its dysregulation may contribute to insulin resistance and obesity.

Quantification of cyclic GMP is typically performed using enzyme immunoassays (EIA) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). These methods measure intracellular or extracellular cGMP concentrations and are used to assess the impact of genetic or pharmacological perturbations.

Guanylyl cyclase and phosphodiesterase activities can be measured using radioactive substrate conversion assays or fluorescent probes. These assays help determine the kinetic properties of enzymes and the effects of mutations.

Genetically encoded cGMP sensors, such as cGES-DE5, allow real-time visualization of cGMP dynamics in living cells. These sensors are valuable for studying spatial and temporal aspects of cGMP signaling in response to stimuli.

Transcriptomics and proteomics can identify global changes in gene expression and protein phosphorylation downstream of cGMP. For example, phosphoproteomics has been used to map cGKI substrates in cardiac myocytes. These approaches provide unbiased insights into cGMP-regulated networks.

Researchers studying cGMP metabolic process-related genes often need to determine whether a candidate gene is causally involved in cGMP regulation or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation of genes in the cGMP pathway.

GO:0046068 (cGMP metabolic process) is a fundamental biological process that governs the synthesis, degradation, transport, and signaling of cyclic GMP. Its dysregulation is implicated in a wide range of human diseases, including cardiovascular disorders, retinal degeneration, and Alzheimer's disease. Advances in CRISPR-based gene editing and omics technologies are enabling precise dissection of the cGMP pathway, offering new opportunities for therapeutic intervention. EDITGENE's comprehensive services support researchers in creating tailored cell models to study cGMP metabolism and its role in health and disease.